NEW YORK ( TheStreet) -- CHANGE IN RATINGSBoston Scientific ( BSX) downgraded at Goldman from Neutral to Sell. Stock also added to the Conviction list, as the company could lose market share. Clorox ( CLX) upgraded at Barclays to Overweight from Equal Weight as the company is experiencing top line momentum. Price target jumped to $71 from $67. 2010 and 2011 EPS estimates set at $4.23 and $4.73, respectively. Coventry Health ( CVH) upgraded at Goldman from Sell to Neutral. Valuation call. Onyx Pharmaceuticals ( ONXX) upgraded at Goldman from Neutral to Buy. $37 price target. Company has an attractive pipeline, and good be an attractive acquisition target. Parexel ( PRXL) upgraded at Goldman to Buy. Company can deliver above-average earnings growth. Psychiatric Solutions ( PSYS) downgraded at Wells from Outperform to Market Perform. Stock is already pricing in a potential buyout. Starbucks ( SBUX) upgraded at UBS from Neutral to Buy. $29 price target. Estimates also raised, given the company's strong sales and earnings momentum. Universal American ( UAM) downgraded at Goldman from Neutral to Sell. Stock was also added to the Conviction list, based on valuation. Pharmasset ( VRUS) initiated at Citi with a Buy rating and $34 price target. RG7128 should become a major drug in the hepatitis C market. Western Union ( WU) downgraded at William Blair from Outperform to Market Perform. Valuation call, as the stock lacks catalysts. Wyndham Worldwide ( WYN) downgraded at Goldman from Buy to Neutral. Valuation call, based on a $26 price target.